Guardant Health struck a strategic partnership with Zephyr AI to combine Guardant’s large multimodal molecular datasets with Zephyr’s AI and machine learning platform to accelerate discovery of genomic and multimodal biomarkers for therapy selection and response monitoring. The collaboration will fold Zephyr analytics into Guardant’s Infinity AI suite for biopharma customers. Guardant said the deal aims to improve predictive models of targeted therapy response by integrating ctDNA, clinical annotations, and other molecular signals. Financial terms were not disclosed; the partnership positions both firms to offer enhanced R&D services to oncology developers. For readers: data‑driven biomarker discovery pairs high‑volume clinical genomics with advanced machine learning to prioritize markers for companion diagnostics and trial enrichment.